menu search

Mannkind’s inhaled clofazimine will advance to an adaptive phase 2/3 study for potential treatment of rare lung disease

Direct delivery of clofazimine to the lungs may provide a treatment option for nontuberculous mycobacterial (NTM) lung disease that potentially overco...

January 23, 2023, 11:05 am

Pulmatrix to present data on pur1800 at the annual meeting of the american academy of allergy, asthma and immunology

LEXINGTON, Mass. , Jan. 23, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative...

January 23, 2023, 9:05 am

Beyond air® schedules third fiscal quarter 2023 financial results conference call and webcast

Call scheduled for Thursday, February 9th at 4:30 pm Eastern Time GARDEN CITY, N.Y., Jan. 17, 2023 (GLOBE NEWSWIRE) — Beyond Air, Inc. (NASDAQ: XAIR...

January 17, 2023, 9:05 pm

Baxter - steak at hamburger prices

Baxter International Inc. ( BAX , Financial) is a health care company that offers a wide range of products and services such as dialysis treatments, I...

January 6, 2023, 11:05 am

Asthma and copd drugs market size to hit usd 34,374.23 million by 2030 at 4.20% cagr – report by market research future (mrfr)

Asthma and COPD Drugs Market Trends, Growth and Insights by Disease (COPD and Asthma), Product (Long-Term Asthma Control Medications, Quick Relief Med...

December 15, 2022, 12:45 am

China 'definitely' needs 2nd covid booster dose: cansino biologics ceo

Yu Xuefeng, chief executive officer of CanSino Biologics Inc., a Tianjin, China-based drugmaker that's rolling out a vaccine that can be...

December 6, 2022, 11:47 pm

Mannkind to present two posters at 22nd annual diabetes technology meeting

WESTLAKE VILLAGE, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercializ...

November 10, 2022, 6:05 am

Mannkind corporation participating at upcoming conferences

WESTLAKE VILLAGE, Calif. and DANBURY, Conn., May 09, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the developmen...

May 9, 2022, 6:00 am

Nrx pharma says i-spy study of inhaled zyesami in critical covid-19 stopped

Quantum Leap Healthcare Collaborative (QLHC) announced that the nebulized form of NRx Pharmaceuticals Inc's (NASDAQ: NRXP) Zyesami (Aviptadil) in th...

March 31, 2022, 1:33 pm

Mannkind corporation to participate in the lytham partners spring 2022 investor conference

DANBURY, Conn., March 28, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of<...

March 28, 2022, 6:05 am

Mannkind corporation to participate in svb leerink 2022 global healthcare conference

DANBURY, Conn., Feb. 10, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of...

February 10, 2022, 6:05 am

Mannkind corporation to participate in svb leerink 2022 global healthcare conference

DANBURY, Conn., Feb. 10, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of...

February 10, 2022, 6:05 am

Mannkind corporation to participate in svb leerink 2022 global healthcare conference

DANBURY, Conn., Feb. 10, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of...

February 10, 2022, 6:05 am

Verona pharma: first inhaled product candidate combining anti-inflammatory and bronchodilator effects, a potential blockbuster

he company's lead product candidate is Ensifentrine, an inhaled PDE3, and PDE4 inhibitor, which is bein...

February 3, 2022, 7:00 pm

Verona pharma: first inhaled product candidate combining anti-inflammatory and bronchodilator effects, a potential blockbuster

he company's lead product candidate is Ensifentrine, an inhaled PDE3, and PDE4 inhibitor, which is bein...

February 3, 2022, 7:00 pm

Verona pharma: first inhaled product candidate combining anti-inflammatory and bronchodilator effects, a potential blockbuster

he company's lead product candidate is Ensifentrine, an inhaled PDE3, and PDE4 inhibitor, which is bein...

February 3, 2022, 7:00 pm


Search within

Pages Search Results: